These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 415967)

  • 41. Rabbit anti-EL4 serum. A reagent with specificity for a population of murine suppressor cells.
    Al-Sakkaf L; Cooke A; Hutchings P; Jones B
    Immunology; 1979 Oct; 38(2):375-83. PubMed ID: 159864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetic analysis of target cell destruction by effector T cells. I. Delineation of parameters related to the frequency and lytic efficiency of killer cells.
    Thorn RM; Henney CS
    J Immunol; 1976 Dec; 117(6):2213-9. PubMed ID: 825577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colony formation of cytolytic T cells in semisolid medium.
    Collavo D; Engers H; Nabholz M
    Eur J Immunol; 1978 Aug; 8(8):595-9. PubMed ID: 308882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Specific spontaneous cytotoxic activity in human T cell colonies.
    Price GB; Teh HS; Miller RG
    J Immunol; 1980 May; 124(5):2352-5. PubMed ID: 6767786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes.
    Rouse BT; Wagner H; Harris AW
    J Immunol; 1972 May; 108(5):1353-61. PubMed ID: 4623947
    [No Abstract]   [Full Text] [Related]  

  • 48. Sensitivity of cloned high- and low-metastatic murine Lewis lung tumor cells to lysis by cytotoxic autoreactive cells.
    Olsson L; Kiger N; Kronstrom H
    Cancer Res; 1981 Nov; 41(11 Pt 1):4706-9. PubMed ID: 6975655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S; Tsuchiya T; Norimura T; Yamashita U
    J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA; Mentzer SJ; Maizel SE
    Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large agranular lymphocytes: early non-specific effector cells in allograft rejection in the mouse.
    Gregory CD; Atkinson ME
    Immunology; 1984 Oct; 53(2):257-65. PubMed ID: 6386672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined cytolytic effect of x irradiation and cell-mediated immune reactions on tumor cells in vitro.
    Song CW; Levitt SH
    Radiology; 1974 Apr; 111(1):211-2. PubMed ID: 4205812
    [No Abstract]   [Full Text] [Related]  

  • 53. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of the immune response to transplantation antigens. V. A comparison of the effects of antilymphocytic serum and enhancing alloantiserum on effector mechanisms of allograft rejection.
    Zola H
    Clin Exp Immunol; 1975 Feb; 19(2):367-76. PubMed ID: 1212805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early steps in specific tumor cell lysis by sensitized mouse T lymphocytes. III. Resolution of two distinct roles for calcium in the cytolytic process.
    Gately MK; Martz E
    J Immunol; 1979 Feb; 122(2):482-9. PubMed ID: 105046
    [No Abstract]   [Full Text] [Related]  

  • 56. Generation and characterization of suppressor cells of the in vitro allograft response.
    Anderson SM; Ferguson RM; Simmons RL
    Surg Forum; 1977; 28():318-20. PubMed ID: 310171
    [No Abstract]   [Full Text] [Related]  

  • 57. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.
    Biddison WE; Palmer JC
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):329-33. PubMed ID: 402006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Augmentation of antigen-specific cytotoxicity by concanavalin A at the peak of response to tumor allografts.
    Shimamoto Y; Nomoto K; Taniguchi K; Kubo C
    Cell Immunol; 1979 Sep; 47(1):204-10. PubMed ID: 92366
    [No Abstract]   [Full Text] [Related]  

  • 59. Natural cell-mediated immunity to lymphoma cells. I. Characteristics of effector cells in a cytostasis assay in vitro.
    Tufveson G; Riesenfeld I; Rönnblom L; Hedman A; Alm GV
    J Natl Cancer Inst; 1977 Nov; 59(5):1491-7. PubMed ID: 302867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of bacille Calmette-Guérin on the immune response of BALB/c mice to a tumor allograft.
    Treagan L; Chen TH; Rambo O; Elberg SS
    J Infect Dis; 1979 Oct; 140(4):541-5. PubMed ID: 117062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.